Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development… Read more
Mabion S.A. (MAB) - Total Liabilities
Latest total liabilities as of September 2025: zł50.44 Million PLN
Based on the latest financial reports, Mabion S.A. (MAB) has total liabilities worth zł50.44 Million PLN as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mabion S.A. - Total Liabilities Trend (2009–2024)
This chart illustrates how Mabion S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mabion S.A. Competitors by Total Liabilities
The table below lists competitors of Mabion S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thai Wah Public Company Limited
BK:TWPC
|
Thailand | ฿2.55 Billion |
|
Muliang Viagoo Technology Inc
PINK:MULG
|
USA | $4.87 Million |
|
Dawon Nexview Co., Ltd.
KQ:323350
|
Korea | ₩14.21 Billion |
|
Unlu Yatirim Holding AS
IS:UNLU
|
Turkey | TL2.35 Billion |
|
Centara Hotels & Resorts Leasehold Property Fund
BK:CTARAF
|
Thailand | ฿900.00K |
|
MicroCloud Hologram Inc.
NASDAQ:HOLO
|
USA | $81.50 Million |
|
Enad Global 7 AB (publ)
PINK:ENADF
|
USA | $1.09 Billion |
|
Formosa Prosonic Industries
KLSE:9172
|
Malaysia | RM102.68 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Mabion S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.42 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mabion S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mabion S.A. (2009–2024)
The table below shows the annual total liabilities of Mabion S.A. from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł48.03 Million | -46.92% |
| 2023-12-31 | zł90.48 Million | -17.50% |
| 2022-12-31 | zł109.67 Million | -16.24% |
| 2021-12-31 | zł130.92 Million | -15.92% |
| 2020-12-31 | zł155.71 Million | +15.23% |
| 2019-12-31 | zł135.12 Million | +31.73% |
| 2018-12-31 | zł102.58 Million | -24.91% |
| 2017-12-31 | zł136.60 Million | +56.09% |
| 2016-12-31 | zł87.52 Million | +32.78% |
| 2015-12-31 | zł65.91 Million | -86.36% |
| 2014-12-31 | zł483.33 Million | +106.43% |
| 2013-12-31 | zł234.13 Million | -89.07% |
| 2012-12-31 | zł2.14 Billion | +32462.22% |
| 2011-12-31 | zł6.58 Million | +282.47% |
| 2010-12-31 | zł1.72 Million | +306.55% |
| 2009-12-31 | zł422.95K | -- |